172 related articles for article (PubMed ID: 37014891)
1. BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images.
Su Z; Niazi MKK; Tavolara TE; Niu S; Tozbikian GH; Wesolowski R; Gurcan MN
PLoS One; 2023; 18(4):e0283562. PubMed ID: 37014891
[TBL] [Abstract][Full Text] [Related]
2. Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
Whitney J; Corredor G; Janowczyk A; Ganesan S; Doyle S; Tomaszewski J; Feldman M; Gilmore H; Madabhushi A
BMC Cancer; 2018 May; 18(1):610. PubMed ID: 29848291
[TBL] [Abstract][Full Text] [Related]
3. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
4. Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings.
Li H; Whitney J; Bera K; Gilmore H; Thorat MA; Badve S; Madabhushi A
Breast Cancer Res; 2019 Oct; 21(1):114. PubMed ID: 31623652
[TBL] [Abstract][Full Text] [Related]
5. Automated Tubule Nuclei Quantification and Correlation with Oncotype DX risk categories in ER+ Breast Cancer Whole Slide Images.
Romo-Bucheli D; Janowczyk A; Gilmore H; Romero E; Madabhushi A
Sci Rep; 2016 Sep; 6():32706. PubMed ID: 27599752
[TBL] [Abstract][Full Text] [Related]
6. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study.
Nam G; Singh K; Lopresti ML; Ouseph MM; Wang LJ; Wang Y
Technol Cancer Res Treat; 2021; 20():15330338211035037. PubMed ID: 34696631
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
[TBL] [Abstract][Full Text] [Related]
8. Deep learning radiopathomics based on preoperative US images and biopsy whole slide images can distinguish between luminal and non-luminal tumors in early-stage breast cancers.
Huang Y; Yao Z; Li L; Mao R; Huang W; Hu Z; Hu Y; Wang Y; Guo R; Tang X; Yang L; Wang Y; Luo R; Yu J; Zhou J
EBioMedicine; 2023 Aug; 94():104706. PubMed ID: 37478528
[TBL] [Abstract][Full Text] [Related]
9. A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models.
Saha A; Harowicz MR; Wang W; Mazurowski MA
J Cancer Res Clin Oncol; 2018 May; 144(5):799-807. PubMed ID: 29427210
[TBL] [Abstract][Full Text] [Related]
10. The Relationship of Race, Oncotype DX, and Ki67 in a Population Highly Screened For Breast Cancer.
Guth AA; Chun Kim J; Schwartz S; Montes J; Snyder RA; Axelrod D; Schnabel F
Breast J; 2017 Mar; 23(2):177-181. PubMed ID: 28299888
[TBL] [Abstract][Full Text] [Related]
11. A deep learning based strategy for identifying and associating mitotic activity with gene expression derived risk categories in estrogen receptor positive breast cancers.
Romo-Bucheli D; Janowczyk A; Gilmore H; Romero E; Madabhushi A
Cytometry A; 2017 Jun; 91(6):566-573. PubMed ID: 28192639
[TBL] [Abstract][Full Text] [Related]
12. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional intra-tumour heterogeneity predicted by deep learning in routine breast histopathology slides provides independent prognostic information.
Wang Y; Ali MA; Vallon-Christersson J; Humphreys K; Hartman J; Rantalainen M
Eur J Cancer; 2023 Sep; 191():112953. PubMed ID: 37494846
[TBL] [Abstract][Full Text] [Related]
14. Recognizing basal cell carcinoma on smartphone-captured digital histopathology images with a deep neural network.
Jiang YQ; Xiong JH; Li HY; Yang XH; Yu WT; Gao M; Zhao X; Ma YP; Zhang W; Guan YF; Gu H; Sun JF
Br J Dermatol; 2020 Mar; 182(3):754-762. PubMed ID: 31017653
[TBL] [Abstract][Full Text] [Related]
15. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
16. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
17. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
18. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
[TBL] [Abstract][Full Text] [Related]
19. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
20. Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer：A multicenter study.
Li B; Li F; Liu Z; Xu F; Ye G; Li W; Zhang Y; Zhu T; Shao L; Chen C; Sun C; Qiu B; Bu H; Wang K; Tian J
Breast; 2022 Dec; 66():183-190. PubMed ID: 36308926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
